Paclitaxel and its semi-synthetic derivatives: comprehensive insights into chemical structure, mechanisms of action, and anticancer properties
European Journal of Medical Research · 30.01.2024 · 29 (1)
DOI: 10.1186/s40001-024-01657-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Medical Research, online erschienen am 30.01.2024. Verfasst von Priyanka Sati und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Kumaun University, Bhimtal, Uttarakhand, India. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 135-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer is a disease that can cause abnormal cell growth and can spread throughout the body. It is among the most significant causes of death worldwide, resulting in approx. 10 million deaths annually. Many synthetic anticancer drugs are available, but they often come with side effects and can interact negatively with other medications. Additionally, many chemotherapy drugs used for cancer treatment can develop resistance and harm normal cells, leading to dose-limiting side effects. As a result, finding effective cancer treatments and developing new drugs remains a significant challenge. However, plants are a potent source of natural products with the potential for cancer treatment. These biologically active compounds may be the basis for enhanced or less toxic derivatives. Herbal medicines/phytomedicines, or plant-based drugs, are becoming more popular in treating complicated diseases like cancer due to their effectiveness and are a particularly attractive option due to their affordability, availability, and lack of serious side effects. They have broad applicability and therapeutic efficacy, which has spurred scientific research into their potential as anticancer agents. This review focuses on Paclitaxel (PTX), a plant-based drug derived from Taxus sp., and its ability to treat specific tumors. PTX and its derivatives are effective against various cancer cell lines. Researchers can use this detailed information to develop effective and affordable treatments for cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, Kumaun University, Bhimtal, Uttarakhand, India.
- Department of Molecular Biology and Biochemistry, Guru Nanak Dev University, Amritsar, Punjab, India.
- Institute for Integrated Natural Sciences, University of Koblenz, Koblenz, Germany.
- Department of Botany, Central University of Jammu, Rahya-Suchani (Bagla), Jammu and Kashmir, India.
- Department of Biology, Brandeis University, Waltham, MA, USA.
- Department of Pharmaceutical Technology, Pharmaceutical School, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
Zitieren
APA
Sati, P., Sharma, E., Dhyani, P., Attri, D. C., Rana, R., Kiyekbayeva, L., Büsselberg, D., Samuel, S. M., & Sharifi-Rad, J. (2024). Paclitaxel and its semi-synthetic derivatives: comprehensive insights into chemical structure, mechanisms of action, and anticancer properties. European Journal of Medical Research, 29(1). https://doi.org/10.1186/s40001-024-01657-2
Vancouver
Sati P, Sharma E, Dhyani P, Attri DC, Rana R, Kiyekbayeva L, et al. Paclitaxel and its semi-synthetic derivatives: comprehensive insights into chemical structure, mechanisms of action, and anticancer properties. European Journal of Medical Research. 2024;29(1). doi:10.1186/s40001-024-01657-2
BibTeX
@article{Sati2024,
author = {Sati, Priyanka and Sharma, Eshita and Dhyani, Praveen and Attri, Dharam Chand and Rana, Rohit and Kiyekbayeva, Lashyn and Büsselberg, Dietrich and Samuel, Samson Mathews and Sharifi-Rad, Javad},
title = {Paclitaxel and its semi-synthetic derivatives: comprehensive insights into chemical structure, mechanisms of action, and anticancer properties},
journal = {European Journal of Medical Research},
year = {2024},
volume = {29},
number = {1},
doi = {10.1186/s40001-024-01657-2}
}
EUVIMED